PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD.
Bianchi A, et al. Among authors: zeybek b.
Gynecol Oncol. 2019 Oct;155(1):144-150. doi: 10.1016/j.ygyno.2019.08.010. Epub 2019 Aug 18.
Gynecol Oncol. 2019.
PMID: 31434613
Free PMC article.